Published in Pediatrics on March 01, 2008
Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology (2009) 4.07
Fast Implementation for Normal Mixed Effects Models With Censored Response. J Comput Graph Stat (2015) 1.15
A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med (2014) 1.01
Skew-normal/independent linear mixed models for censored responses with applications to HIV viral loads. Biom J (2012) 0.89
CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. J Acquir Immune Defic Syndr (2011) 0.88
Initial Validation of the HIV Treatment Regimen Fatigue Scale for Adults Prescribed Antiretroviral Therapy. J Assoc Nurses AIDS Care (2015) 0.80
Paediatric HIV and elimination of mother-to-child transmission of HIV in the ASEAN region: a call to action. AIDS Care (2011) 0.78
Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA. J Int AIDS Soc (2016) 0.75
Quantile regression for censored mixed-effects models with applications to HIV studies. Stat Interface (2016) 0.75
Mutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAART. PLoS One (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol (2003) 5.43
Identification of a candidate therapeutic autophagy-inducing peptide. Nature (2013) 3.76
Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med (2015) 3.75
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Human bocavirus: prevalence and clinical spectrum at a children's hospital. Clin Infect Dis (2006) 2.38
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis (2010) 2.15
Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol (2011) 2.06
Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet (2003) 2.04
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis (2004) 1.98
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother (2007) 1.94
Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology (2008) 1.94
[Estimating the 2006 prevalence of HIV by gender and risk groups in Tijuana, Mexico]. Gac Med Mex (2009) 1.86
Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses (2007) 1.84
Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: seroprevalence and correlates of HIV infection. J Acquir Immune Defic Syndr (2006) 1.83
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog (2012) 1.69
Human immunodeficiency virus type-1 infection inhibits autophagy. AIDS (2008) 1.65
Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis (2006) 1.64
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr (2004) 1.60
Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr (2012) 1.58
Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. J Pediatr (2006) 1.57
Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr (2011) 1.55
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS (2007) 1.53
Hormonally active vitamin D3 (1alpha,25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem (2011) 1.48
Adolescents and HIV infection: the pediatrician's role in promoting routine testing. Pediatrics (2011) 1.47
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr (2009) 1.46
Randomized controlled trial of emergency transjugular intrahepatic portosystemic shunt versus emergency portacaval shunt treatment of acute bleeding esophageal varices in cirrhosis. J Gastrointest Surg (2012) 1.45
HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis (2010) 1.40
Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis (2004) 1.37
HIV prevalence during pregnancy in Tijuana, Baja California, Mexico. AIDS (2003) 1.36
Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol (2006) 1.33
Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr (2007) 1.32
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis. AIDS Behav (2010) 1.26
Ethical considerations in scientific writing. Indian J Sex Transm Dis (2011) 1.25
Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol (2005) 1.18
Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother (2004) 1.18
Predictors of immunologic long-term nonprogression in HIV-infected children: implications for initiating therapy. J Allergy Clin Immunol (2005) 1.18
Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis (2006) 1.16
Modelling HIV viral rebound using non-linear mixed effects models. Stat Med (2002) 1.14
Toll-like receptor 8 ligands activate a vitamin D mediated autophagic response that inhibits human immunodeficiency virus type 1. PLoS Pathog (2012) 1.13
Age and temporal trends of total physical activity in Swedish men. Med Sci Sports Exerc (2003) 1.12
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J (2003) 1.11
An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS (2005) 1.11
Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. J Infect Dis (2004) 1.11
Clearance of Cellulosimicrobium cellulans bacteremia in a child without central venous catheter removal. J Clin Microbiol (2006) 1.09
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis (2012) 1.09
Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. AIDS Res Hum Retroviruses (2010) 1.08
Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug Alcohol Depend (2009) 1.08
Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr (2007) 1.07
Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol (2007) 1.07
HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence. AIDS Behav (2012) 1.06
Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics (2009) 1.06
Lifetime suicidal ideation and attempt are common among HIV+ individuals. J Affect Disord (2011) 1.06
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis (2013) 1.05
Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis (2003) 1.05
Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab (2012) 1.04
Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals. J Acquir Immune Defic Syndr (2008) 1.04
Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol (2004) 1.03
Random changepoint modelling of HIV immunologic responses. Stat Med (2007) 1.02
Autophagy is increased in postmortem brains of persons with HIV-1-associated encephalitis. J Infect Dis (2011) 1.02
HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J Infect Dis (2013) 1.02
Role of metabolic syndrome components in human immunodeficiency virus-associated stroke. J Neurovirol (2009) 1.01
Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis (2012) 1.00
Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells. J Virol (2004) 1.00
Test-retest stability of calibrated BOLD-fMRI in HIV- and HIV+ subjects. Neuroimage (2010) 1.00
Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol (2003) 1.00
Undiagnosed respiratory viruses in children. Pediatrics (2008) 0.99
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother (2010) 0.98
Human metapneumovirus associated with central nervous system infection in children. Pediatr Infect Dis J (2009) 0.98
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J (2010) 0.97
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis (2013) 0.97
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother (2013) 0.97
An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J Allergy Clin Immunol (2008) 0.97
Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood (2007) 0.97
Randomized trial of emergency endoscopic sclerotherapy versus emergency portacaval shunt for acutely bleeding esophageal varices in cirrhosis. J Am Coll Surg (2009) 0.97
Host genetic determinants of human immunodeficiency virus infection and disease progression in children. Pediatr Res (2009) 0.96
Human cytomegalovirus-specific CD4+-T-cell cytokine response induces fractalkine in endothelial cells. J Virol (2004) 0.96
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother (2012) 0.95
Impact of pregnancy on abacavir pharmacokinetics. AIDS (2006) 0.95
Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy. Med Care (2005) 0.95
Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. J Adolesc Health (2010) 0.95
Production of interferon α by human immunodeficiency virus type 1 in human plasmacytoid dendritic cells is dependent on induction of autophagy. J Infect Dis (2012) 0.95
High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage. Blood (2007) 0.95
Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother (2007) 0.95
The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol (2004) 0.95
Predictors of highly active antiretroviral therapy utilization for behaviorally HIV-1-infected youth: impact of adult versus pediatric clinical care site. J Adolesc Health (2011) 0.95
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS (2009) 0.95
Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis (2002) 0.94
CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells. J Biol Chem (2008) 0.94
Conformity of pediatric/adolescent HIV clinics to the patient-centered medical home care model. AIDS Patient Care STDS (2013) 0.94